乳腺导管内原位癌浸润机制

国际肿瘤学杂志››2018,Vol. 45››Issue (6): 368-370.doi:0.3760/cma.j.issn.1673-422X.2018.06.012

李智宇，吴奇，孙圣荣

430060 武汉大学人民医院乳腺甲状腺外科

收稿日期:2017-12-27出版日期:2018-06-08发布日期:2018-07-31
通讯作者:孙圣荣 E-mail:sun137@sina.com
基金资助:

国家自然科学基金（81471781）

Mechanism of ductal carcinoma in situ to invasive breast cancer

Li Zhiyu, Wu Qi, Sun Shengrong

Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China

Received:2017-12-27Online:2018-06-08Published:2018-07-31
Contact:Sun Shengrong E-mail:sun137@sina.com
Supported by:

National Natural Science Foundation of China (81471781)

摘要/Abstract

摘要：乳腺导管内原位癌被认为是浸润性导管癌的前驱病变，若未经治疗，约40%的原位癌病变可进展为浸润性癌。在乳腺导管内原位癌的浸润转化过程中，肿瘤微环境、驱动基因、信号通路和表观遗传等发挥了重要作用。深入研究乳腺导管内原位癌向浸润性癌转化的过程将有利于推动对乳腺导管内原位癌个体化的精准评估，可更好地预测乳腺导管内原位癌的预后，以期找出一个对患者最有利的综合评定标准，在过度与低度治疗间找到平衡点。

李智宇，吴奇，孙圣荣. 乳腺导管内原位癌浸润机制[J]. 国际肿瘤学杂志, 2018, 45(6): 368-370.

Li Zhiyu, Wu Qi, Sun Shengrong. Mechanism of ductal carcinoma in situ to invasive breast cancer[J]. Journal of International Oncology, 2018, 45(6): 368-370.

参考文献

［1］ Siziopikou KP. Ductal carcinoma in situ of the breast: current concepts and future directions［J］. Arch Pathol Lab Med, 2013, 137(4): 462-466. DOI: 10.5858/arpa.2012-0078-RA. ［2］ Cowell CF, Weigelt B, Sakr RA, et al. Progression from ductal carcinoma in situ to invasive breast cancer: revisited［J］. Mol Oncol, 2013, 7(5): 859-869. DOI: 10.1016/j.molonc.2013.07.005. ［3］ Pandey PR, Saidou J, Watabe K. Role of myoepithelial cells in breast tumor progression［J］. Front Biosci (Landmark Ed), 2010, 15: 226-236. DOI: 10.2741/3617. ［4］ Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression［J］. J Pathol, 2011, 223(2): 307-317. DOI: 10.1002/path.2808. ［5］ Elias EV, de Castro NP, Pineda PH, et al. Epithelial cells captured from ductal carcinoma in situ reveal a gene expression signature associated with progression to invasive breast cancer［J］. Oncotarget, 2016, 7(46): 75672-75684. DOI: 10.18632/oncotarget.12352. ［6］ Rakha EA, Miligy IM, Gorringe KL, et al. Invasion in breast lesions: the role of the epithelialstroma barrier［J］. Histopathology, 2018, 72(7): 1075-1083. DOI: 10.1111/his.13446. ［7］ Ma XJ, Dahiya S, Richardson E, et al. Gene expression profiling of the tumor microenvironment during breast cancer progression［J］. Breast Cancer Res, 2009, 11(1): R7. DOI: 10.1186/bcr2222. ［8］ Witkiewicz AK, Cox DW, Rivadeneira D, et al. The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2positive breast cancer［J］. Oncogene, 2014, 33(30): 3980-3991. DOI: 10.1038/onc.2013.367. ［9］ Malanchi I, SantamariaMartinez A, Susanto E, et al. Interactions between cancer stem cells and their niche govern metastatic colonization［J］. Nature, 2011, 481(7379): 85-89. DOI: 10.1038/nature 10694. ［10］ Espina V, Liotta LA. What is the malignant nature of human ductal carcinoma in situ［J］. Nat Rev Cancer, 2011, 11(1): 68-75. DOI: 10.1038/nrc2950. ［11］ SensAbuázar C, Napolitano E Ferreira E, Osório CA, et al. Downregulation of ANAPC13 and CLTCL1: early events in the progression of preinvasive ductal carcinoma of the breast［J］. Transl Oncol, 2012, 5(2): 113-123. ［12］ Hsu TH, Jiang SY, Chan WL, et al. Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells［J］. Cell Death Differ, 2014, 22(5): 801-814. DOI: 10.1038/cdd.2014.175. ［13］ Benjamin DI, Louie SM, Mulvihill MM, et al. Inositol phosphate recycling regulates glycolytic and lipid metabolism that drives cancer aggressiveness［J］. ACS Chem Biol, 2014, 9(6): 1340-1350. DOI: 10.1021/cb5001907. ［14］ Wang L, Lyu S, Wang S, et al. Loss of FAT1 during the progression from DCIS to IDC and predict poor clinical outcome in breast cancer［J］. Exp Mol Pathol, 2016, 100(1): 177-183. DOI: 10.1016/j.yexmp.2015.12.012. ［15］ Perez AA, Balabram D, Rocha RM, et al. Coexpression of p16, Ki67 and COX2 is associated with basal phenotype in highgrade ductal carcinoma in situ of the breast［J］. J Histochem Cytochem, 2015, 63(6): 408-416. DOI: 10.1369/0022155415576540. ［16］ Sakr RA, Weigelt B, Chandarlapaty S, et al. PI3K pathway activation in HighGrade ductal carcinoma in SituImplications for progression to invasive breast carcinoma［J］. Clin Cancer Res, 2014, 20(9): 2326-2337. DOI: 10.1158/10780432.CCR132267. ［17］ Shi A, Dong J, Hilsenbeck S, et al. The status of STAT3 and STAT5 in human breast atypical ductal hyperplasia［J］. PLoS One, 2015, 10(7): e0132214. DOI: 10.1371/journal.pone.0132214. ［18］ Park SY, Kwon HJ, Lee HE, et al. Promoter CpG island hypermethylation during breast cancer progression［J］. Virchows Arch, 2011, 458(1): 73-84. DOI: 10.1007/s00428-010-1013-6. ［19］ Moelans CB, VerschuurMaes AH, van Diest PJ. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer［J］. J Pathol, 2011, 225(2): 222-231. DOI: 10.1002/path.2930. ［20］ Hannafon BN, Ding WQ. miRNAs as biomarkers for predicting the progression of ductal carcinoma in situ［J］. AM J Pathol, 2018, 188(3): 542-549. DOI: 10.1016/j.ajpath.2017.11.003. ［21］ Li S, Meng H, Zhou F, et al. MicroRNA132 is frequently downregulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation［J］. Pathol Res Pract, 2013, 209(3): 179-183. DOI: 10.1016/j.prp.2012.12.002. ［22］ Farazi TA, Horlings HM, Ten Hoeve JJ, et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing［J］. Cancer Res, 2011, 71(13): 4443-4453. DOI: 10.1158/0008-5472.CAN-11-0608. ［23］ Galasso M, Costantino G, Pasquali L, et al. Profiling of the predicted circular RNAs in ductal in situ and invasive breast cancer: a pilot study［J］. Int J Genomics, 2016, 2016: 4503840. DOI: 10.1155/2016/4503840.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[7]	顾芳萌, 徐晨阳, 雷大鹏.人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[8]	张文馨, 夏泠, 彭晋, 周福祥.甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[9]	王昆, 周中新, 臧其威.血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[10]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇.信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[11]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[12]	胡婷婷, 王越华.电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[13]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[14]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙.肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[15]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.